Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» ITMN's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ITMN Guru Trades in

Q2 2014

ITMN Guru Trades in Q2 2014

Jim Simons 426,129 sh (New)
Joel Greenblatt 6,487 sh (New)
Steven Cohen 240,600 sh (unchged)
Columbia Wanger Sold Out
Chuck Royce 278,000 sh (-15.24%)
PRIMECAP Management 4,525,925 sh (-31.71%)
» More
Q3 2014

ITMN Guru Trades in Q3 2014

Mario Gabelli 60,000 sh (New)
Jim Simons Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
PRIMECAP Management Sold Out
Joel Greenblatt Sold Out
» More
Q4 2014

ITMN Guru Trades in Q4 2014

Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ITMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:IUX.Germany,

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

Guru Investment Theses on InterMune Inc

Mario Gabelli Comments on InterMune Inc - Oct 28, 2014

InterMune Inc. (ITMN) is a California based biotechnology company focused on the research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. On August 24, 2014, InterMune received a $74 cash per share tender offer from Swiss pharmaceuticals company Roche Holding AG, valuing the company at $8.3 billion. The offer was conditioned on tender acceptance of a majority of InterMune’s outstanding shares. The offer successfully concluded on September 29, 2014. The Fund earned a 13.2% return.

From Mario Gabelli (Trades, Portfolio)’s ABC Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $111.4
EPS (TTM) $ -2.59
Short Percentage of Float13.51%
52-Week Range $10.95 - 74.24
Shares Outstanding (Mil)107.97

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)